A AB BS S T TR RA AC CT T Primary pancreatic lymphoma (PPL) is a very rare tumor of the pancreas and can mimic pancreatic adenocarcinoma (PAC) clinically and radiographically. The rarity of PPL and its similarity to PAC can potentially lead to misdiagnosis of a minority of potentially curable patients. However, the management of PPL differs greatly from that of PAC. The most appropriate way of diagnosis in these patients is fine-needle aspiration biopsy before surgery. We report two cases with PPL presenting with a mass in the pancreas. One the patients was diagnosed after major open surgery and the other one was diagnosed by fine-needle aspiration biopsy.
rimary pancreatic lymphoma (PPL) is an uncommon form of extranodal non-Hodgkin's lymphoma (NHL) and potentially curable without surgical resection.
The incidence of PPL is estimated to be less than 1% of all NHL and 0.2-4.9% of all pancreatic malignancies. 1, 2 However, involvement of the pancreas by NHL has been frequently reported. 3, 4 PPL is defined as involvement of only pancreatic tissue or additional involvement of pancreatic lymph nodes without any organ or lymph node. 5 PPL can mimic pancreatic adenocarcinoma (PAC) clinically and radiographically. Treatment and prognosis of these tumors are utterly different. Therefore, PPL and PAC must be diagnosed accurately. PPL has a high cure rate with chemotherapy and/or radiotherapy. However, the diagnosis of PPL is very difficult before surgery. [6] [7] [8] Hematology
Kaynar et al
We re port two ca ses of PPL pre sen ting with a mass in the pan cre as. One of the pa ti ents was di agno sed af ter ma jor open sur gery and the ot her one was di ag no sed by fi ne-ne ed le as pi ra ti on bi opsy.
CA SE RE PORTS

CA SE 1
A 58-ye ar-old fe ma le was ad mit ted to our hos pi tal du e to ab do mi nal pa in in Sep tem ber 2007. She had se ven ki log rams of we ight loss in 15 days. Physi cal exa mi na ti on re ve a led a pal pab le non-ten der epigas tric mass and ic te ric scle ra. The pa ti ent had a nor mal blo od co unt. Bi oc he mi cal in ves ti ga ti on reve a led the fol lo wing va lu es: to tal bi li ru bin 7.84 mg/dl; ala ni ne ami not rans fe ra se (ALT) 471 U/l; aspar ta te ami not rans fe ra se (AST) 269 U/l; gam ma glu tamyl trans pep ti da se (GGT) 434 U/l and al ka li ne phosp ha ta se (ALP) 445 U/l. A tu mor mar ker, serum car bohy dra te an ti gen , was found in cre a sed as 83,71 U/ml (Nor mal ran ge 0-31 U/ml). Ab do mi nal ul tra so und (US) re ve a led a mass in the he ad of the pan cre as and ab do mi nal com pute ri zed to mog raphy (ACT) con fir med a 5 x 6.5 cm mass with di la ta ti on of bi le duct and nor mal gallblad der ima ge. ACT with an gi og raphy re ve a led the mass that in va ded the su pe ri or me sen te ric ve in with mul tip le lympha de no pat hi es in the pe ri pancre a tic re gi on that we re me a su red as 2.5 cm.
Per cu ta ne o us trans he pa tic cho lan gi og raphy (PTC) con fir med the di la ta ti on of the pro xi mal bile duct and ste no sis of the dis tal bi le duct du e to exter nal com pres si on cha rac te ri zed by sho ul der sign (Fi gu re 1). Per cu ta ne o us trans he pa tic dra i na ge was per for med. The pa ti ent un der went sur gi cal re secti on of the tu mor by me ans of a mo di fi ed Whipple's pro ce du re and Ro ux-n-Y re cons truc ti on of the gas tro in tes ti nal tract. Pat ho lo gic exa mi na ti on of the sur gi cal spe ci men re ve a led ma lig nant lymphoma. Tu mor cells con sis ted of lar ge and aty pi cal lymphocy tes (Fi gu re 2a) and pos ses sed po si ti vity for CD 20, a B cell mar ker pro te in, (Fi gu re 2b), CD 79 alp ha and al so for Ki-67 in dex (82%). Tu mor cells we re ne ga ti ve for the T cell mar ker pro te in CD 3. The di ag no sis was dif fu se lar ge B-cell lympho ma sta ge II E ac cor ding to Ann Ar bor Clas si fica ti on (Fi gu re 2c).
Che mot he rapy pro to col was imp le men ted as six cycles of CHOP (cyclop hosp ha mi de, do xo ru bicin, vin cris ti ne, and pred ni so ne) and eight cycles of ri tu xi mab. In the fol low -up pe ri od, the pa ti ent was in comp le te re mis si on.
CA SE 2
A 61-ye ar-old fe ma le was ad mit ted to hos pi tal with the comp la ints of ab do mi nal pa in and ja un di ce in Sep tem ber 2008. Physi cal exa mi na ti on re ve a led a pal pab le non-ten der mass in the epi gas tric re gi on and ic te ric scle ra and skin. Se di men ta ti on was 130 mm/h and blo od co unt was nor mal. Bi oc he mi cal in ves ti ga ti on re ve a led the fol lo wing va lu es: to tal bi li ru bin, 11,25 mg/dl; ALT, 626 U/l; AST, 360 U/l; GGT, 495 U/l and ALP, 158 U/l. US and CT ima gina ti ons of the ab do men re ve a led the mass (Fi gu re 3a). PTC re ve a led di la ta ti on of the pro xi mal bi le duct and ste no sis of the dis tal bi le duct by ex ter nal com pres si on of mass cha rac te ri zed by sho ul der sign (Fi gu re 3b). CT-gu i ded fi ne-ne ed le as pi ra ti on biopsy (FNAB) was per for med. Pat ho lo gic exa mi nati on re ve a led a ma lig nant lympho ma. Tu mor cells 
DIS CUS SI ON
NHL fre qu ently oc curs at pri mary ex tra no dal sites, most com monly in the gas tro in tes ti nal tract Hematology Kaynar et al and ra rely in the pan cre as. 9 Cli ni cally, PPL usu ally pre sents with the symptoms of the pan cre a tic head car ci no ma. Ab do mi nal pa in, we ight loss, ja undi ce, acu te pan cre a ti tis and small bo wel obs truc ti on are cli ni cal ma ni fes ta ti ons. Ele va ti on of tran sa mi na ses, ALP and di rect bi li ru bin are com mon fin dings of both pan cre a tic ma lig nan cies. 10 Ti an et al sug ges ted that CA 19-9 le vel es senti ally re ma i ned nor mal thro ug ho ut the co ur se of PAC tu mors smal ler than 5 cm in di a me ter, and CA 19-9 may be a use ful in di ca tor of tre at ment in pa ti ents with re sec tab le tu mors. 11 It may al so incre a se in ot her ma lig nan ci es inc lu ding PPL in vading par ti cu larly the up per gas tro in tes ti nal tract as des cri bed in the first ca se. 12 CA 19-9 le vel was mildly high in our first ca se at the be gin ning, but it was not me a su red in the se cond ca se. The re fo -re, PPL can not be dif fe ren ti a ted from PAC either cli ni cally or la bo ra tory investigations un less the di ag no sis is ba sed on the his to pat ho lo gi cal exa mina ti on.
Ima ging tech ni qu es, such as US and CT scan, are very im por tant in the di ag no sis and sta ging of pan cre a tic mas ses. Merk le et al. re por ted that the pre sen ce of a bulky lo ca li zed tu mor in the pan creas wit ho ut any sig ni fi cant di la ti on of the ma in pancre a tic duct sup ports a di ag no sis of pan cre a tic lympho ma over ade no car ci no ma. They des cri bed ima ging fin dings in pan cre a tic lympho ma and they conc lu ded that two dif fe rent morp ho lo gic pat terns of pan cre a tic in vol ve ment are se en on CT: a lo cali zed, well-cir cums cri bed tu mo ral form and a dif fuse en lar ge ment in fil tra ting or rep la cing most of the pan cre a tic gland. 13 CT imaging of our ca ses re ve aled a mass lo ca ted at the he ad of pan cre as.
In case PPL is included in the dif fe ren ti al di agno sis, bi opsy of the pan cre a tic mass may avo i d surgi cal pro ce du re. 14 FNAB of pan cre a tic mas ses is con si de red a sa fe, ra pid, and easy pro ce du re with high di ag nos tic ac cu racy. Fis her et al. re por ted their ex pe ri en ce abo ut en dos co pic ul tra so und-gu i ded fi ne-ne ed le as pi ra ti on bi opsy re gar ding so lid pancre a tic le si ons. They ob ser ved sen si ti vity, spe ci ficity, po si ti ve pre dic ti ve va lu e, ne ga ti ve pre dic ti ve va lu e, ac cu racy and fal se-ne ga ti ve ra te of en dos copic ul tra so und-gu i ded fi ne-ne ed le as pi ra ti on biopsy as 94.3%, 100%, 100%, 72.2%, 95% and 5%, res pec ti vely. 15 FNAB is valuable in the di ag no sis of PPL. In most of the pa ti ents, the di ag no sis can be es tab lis hed wit ho ut sur gery. La pa ro tomy may be re qu i red for de fi ni ti ve di ag no sis in so me ca ses. 16 The first ca se was di ag no sed af ter ma jor open surgery, ho we ver the se cond one was di ag no sed by fine-ne ed le as pi ra ti on bi opsy ac cu ra tely.
Tre at ments of PPL and ot her pan cre a tic malig nan ci es are dif fe rent. Pe ri am pul lary tu mors except PPL are tre a ted by Whipp le pan cre a ti co du ode nec tomy which car ri es high ope ra ti ve and pos tope ra ti ve mor bi dity and mor ta lity. 17, 18 In li te ra tu re, it was ci ted that PPL pa ti ents tre a ted with che mothe rapy and/or ra di ot he rapy -wit ho ut re sec ti ondid not ha ve wor se out co mes than ope ra ted pa ti ents. 2, 14 a (Hematoxylin-eosin x100) b (Immunoperoxidase x200) Che mot he rapy is the tre at ment of cho i ce for most pa ti ents with PPL. The most com mon chemot he ra pe u tic re gi men inc lu des cyclop hosp ha mide, do xo ru bi cin, vin cris ti ne and pred ni so ne. Comp le te re mis si on can be ex pec ted with che mothe rapy in 63% to 77% of pa ti ents with lar ge B-cell lympho ma. Ri tu xi mab is a mo noc lo nal an ti body direc ted aga inst the CD20 an ti gen. It has be en combi ned with CHOP re sul ting in im pro ved res pon se ra tes up to 85%, and long-term sur vi val in the se pati ents. 19 Ra di ot he rapy has only li mi ted use in the tre at ment of PPL. 14 Po ten ti al con cerns abo ut the sa fety of ra di ot he rapy in this re gi on may be un neces sary, as to xi city has be en subs tan ti ally re du ced with thre e di men si o nal tre at ment plan ning and con for mal de li very of ra di ot he rapy. 20 Af ter the che mot he rapy, both of the pa ti ents had comp le te re mis si on in fol low-up pe ri od alt ho ugh the se cond pa ti ent has not un der go ne to tu mor re sec ti on. .
In conc lu si on, PPL sho uld be con si de red in the dif fe ren ti al di ag no sis of pan cre a tic tu mors be ca u se tre at ment and prog no sis of PPL are ut terly dif ferent. The di ag no sis of PPL is ba sed on his to pat holo gi cal exa mi na ti on. The simp lest way for di ag no sis is FNAB be fo re sur gery. FNAB sho uld be plan ned in all pa ti ents with a sus pec ted PPL in ima ging studi es.
